Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus THEELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus THEELIN.
NORGESTIMATE AND ETHINYL ESTRADIOL vs THEELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
Estrogen receptor agonist; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and promoting estrogenic effects.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
Intramuscular: 0.22 to 1.1 mg (220 to 1100 mcg) once weekly for menopausal symptoms; 0.5 to 2 mg (500 to 2000 mcg) once weekly for prostatic carcinoma.
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
Terminal elimination half-life: 13–19 hours (mean 16 h); clinical context: supports once-daily dosing for estrogen replacement.
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Renal: ~50% as glucuronide and sulfate conjugates; fecal: ~30% via enterohepatic recirculation; biliary: ~20%.
Category D/X
Category C
Estrogen
Estrogen